RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.
XPeng Shares Are Trading Higher Today: What’s Going On?
XPeng Inc (NYSE: XPEV) shares are trading higher Tuesday, rebounding after falling Monday amid news of Xi Jinping's third term.